Methyl selenocysteine: Single-dose pharmacokinetics in men

James R. Marshall, Clement Ip, Karen Romano, Gerald Fetterly, Marwan Fakih, Borko Jovanovic, Marjorie Perloff, James Crowell, Warren Davis, Renee French-Christy, Alexander Dew, Margerie Coomes, Raymond Bergan

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.

Original languageEnglish (US)
Pages (from-to)1938-1944
Number of pages7
JournalCancer Prevention Research
Issue number11
StatePublished - Nov 2011
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Methyl selenocysteine: Single-dose pharmacokinetics in men'. Together they form a unique fingerprint.

Cite this